Trials / Not Yet Recruiting
Not Yet RecruitingNCT06906731
A Study of SHR-9803 for Injection in Patients With Advanced Solid Tumors
An Open-label, Multicenter Phase I/II Study of Safety, Tolerability,Pharmacokinetics and Efficacy of SHR-9803 for Injection in Patients With Advanced Solid Tumors
- Status
- Not Yet Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is an open label, multi-center, multiple doses Phase I/II study to evaluate the safety, tolerability ,pharmacokinetics and efficacy of SHR-9803 for injection in subjects with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-9803 | SHR-9803 |
Timeline
- Start date
- 2025-04-01
- Primary completion
- 2027-06-01
- Completion
- 2027-12-01
- First posted
- 2025-04-02
- Last updated
- 2025-04-02
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06906731. Inclusion in this directory is not an endorsement.